← Back to Search

Topical Immunomodulator

Eucrisa for Eczema

Phase 1
Waitlist Available
Led By Lindsay C Strowd, MD, FAAD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Must not have
Use of prescription topical therapy for atopic dermatitis (e.g., corticosteroids or retinoids) within the past 2 weeks
The use of systemic therapy for atopic dermatitis within the past 4 weeks
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to study a medication for atopic dermatitis. The study will monitor how often the medication is used to help determine how well it works.

Who is the study for?
This trial is for males and females aged 2-64 with mild to moderate atopic dermatitis covering 5% or more of their body. Participants must be able to follow the study procedures, provide consent, and not be using certain other treatments or have conditions that would increase risk.
What is being tested?
The effectiveness of Eucrisa (crisaborole) ointment in treating atopic dermatitis is being tested. Patients will apply it twice daily for a year, with usage monitored by special caps on the tubes. An online survey aims to improve adherence.
What are the potential side effects?
While specific side effects are not listed here, common ones associated with topical treatments like Eucrisa may include skin irritation, burning or stinging upon application, and possible allergic reactions.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I haven't used prescription skin creams for eczema in the last 2 weeks.
Select...
I haven't used systemic therapy for eczema in the last 4 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adherence to topical Therapy
Secondary study objectives
Adherence to topical therapy #1
Therapeutic procedure
Adherence to topical therapy #3
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2 - Online Treatment ResponseExperimental Treatment2 Interventions
Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
Group II: Arm 1 - Standard of CareActive Control1 Intervention
Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,394 Previous Clinical Trials
2,460,008 Total Patients Enrolled
6 Trials studying Eczema
618 Patients Enrolled for Eczema
Lindsay C Strowd, MD, FAADPrincipal InvestigatorWake Forest University Health Sciences

Media Library

Eucrisa (Topical Immunomodulator) Clinical Trial Eligibility Overview. Trial Name: NCT03250663 — Phase 1
Eczema Research Study Groups: Arm 1 - Standard of Care, Arm 2 - Online Treatment Response
Eczema Clinical Trial 2023: Eucrisa Highlights & Side Effects. Trial Name: NCT03250663 — Phase 1
Eucrisa (Topical Immunomodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03250663 — Phase 1
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top